In this study of 20 patients with newly diagnosed sJIA treated off glucocorticoids, fever was controlled after a single injection in all patients, and 16 patients reached the primary outcome of remission after three injections, said Gerd Horneff, MD, PhD, Asklepios Children 's Hospital, Sankt Augustin, Germany.
At enrollment, patients were scheduled to receive three injections of canakinumab at monthly intervals during an active treatment phase, after which they entered an observation phase lasting 40 weeks. In the event of nonresponse or flares in either phase, they were transitioned to usual care.After the first injection, active joint disease and all systemic manifestations resolved in 16 of the 20 patients.
At week 24, or 3 months after the last injection, there was still no joint activity in 16 patients. Systemic manifestations remained controlled in 13 patients, but one patient by this point had a flare. Another flare occurred after this point, and other patients have not yet completed the 52-week observation period.
Among the studies planned for follow-up, investigators will examine genomic and gene activation in relation to disease activity and the effect of canakinumab.
Source: Healthcare Press (healthcarepress.net)
Juvenile Ra Juvenile Idiopathic Arthritis Rheumatoid Arthritis RA - Rheumatoid Arthritis Rheumatoid Arthritis (RA) Glucocorticosteroids Glucocorticoid Therapy Glucocorticoid Steroids Biologic Therapy Biologics Arthritis Joint Inflammation Remission Arthralgia Painful Joint Joint Pain Children Child Childhood Pediatrics Kids Fever Pyrexia
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: denverpost - 🏆 13. / 72 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: sdut - 🏆 5. / 95 Read more »
Source: wjxt4 - 🏆 246. / 63 Read more »
Source: ksatnews - 🏆 442. / 53 Read more »
Source: AP - 🏆 728. / 51 Read more »